Celgene wins NICE yes for Vidaza thanks to patient access scheme
This article was originally published in Scrip
Executive Summary
After six hearings and one appeal, Celgene has convinced NICE, the health technology appraisal institute for England and Wales, to recommend its life-extending anticancer (5-azacitidine) for treating NHS patients with myelodysplastic syndromes (MDS). A new patient access scheme persuaded the institute that the drug would be a cost-effective use of NHS resources.